Mucopolysaccharidosis Type Vi Forecast In 30 Major Markets 2018-2028

  • ID: 4587531
  • Report
  • Region: Global
  • 86 pages
  • Black Swan Analysis
1 of 3

Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux–Lamy syndrome, is an inherited autosomal recessive genetic disorder in which glycosaminoglycans (GAGs) are accumulated in lysosomes due to mutations that cause loss of function of an enzyme responsible for degrading GAGs. The disorder manifests with a broad spectrum of possible clinical presentations, with skeletal deformities, neurological complications and cardiac dysfunction being most common. MPS VI constitutes a burden to the patients and their families as the disease progresses and the patients develop mobility impairment, heart problems and corneal clouding.

This report provides the current prevalent population for MPS VI across 30 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Portugal, Czech Republic, Lithuania, Estonia, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, MPS VI patients grouped by disease severity and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of MPS VI include:

  • Cardiac valvular dysfunction
  • Heart failure
  • Recurrent airway (pneumonia, sinusitis) and ear (otitis media) infections
  • Respiratory failure
  • Obstructive sleep apnoea
  • Pulmonary hypertension
  • Joint disease
  • Cervical spine compression
  • Hydrocephalus
  • Glaucoma
  • Deafness
  • Umbilical and inguinal hernia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reasons to buy

  • Ability to quantify patient populations in global MPS VI market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of MPS VI and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the prevalent population of MPS VI patients.
  • Identification of MPS VI patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of MPS VI patients.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables and Figures
INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR MUCOPOLYSACCHARIDOSIS TYPE VI
FEATURES OF MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS
COMORBIDITIES OF MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List of Tables and Figures

Table 1. Characteristics of the three subtypes of MPS VI
Table 2. Prevalence of MPS VI, total (000s)
Table 3. Prevalence of MPS VI, males (000s)
Table 4. Prevalence of MPS VI, females (000s)
Table 5. Patients with MPS VI by severity, total (000s)
Table 6. MPS VI patients with aortic regurgitation, total (000s)
Table 7. MPS VI patients with mitral regurgitation, total (000s)
Table 8. MPS VI patients with pulmonary regurgitation, total (000s)
Table 9. MPS VI patients with mitral valve stenosis, total (000s)
Table 10. MPS VI patients with aortic valve stenosis, total (000s)
Table 11. Abbreviations and acronyms used in the report
Table 12. USA prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 13. USA prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 14. Canada prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 15. Canada prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 16. France prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 17. France prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 18. Germany prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 19. Germany prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 20. Italy prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 21. Italy prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 22. Spain prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 23. Spain prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 24. UK prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 25. UK prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 26. Poland prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 27. Poland prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 28. Netherlands prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 29. Netherlands prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 30. Belgium prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 31. Belgium prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 32. Norway prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 33. Norway prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 34. Sweden prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 35. Sweden prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 36. Denmark prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 37. Denmark prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 38. Austria prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 39. Austria prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 40. Switzerland prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 41. Switzerland prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 42. Portugal prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 43. Portugal prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 44. Czech Republic prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 45. Czech Republic prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 46. Lithuania prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 47. Lithuania prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 48. Estonia prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 49. Estonia prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 50. Russia prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 51. Russia prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 52. Turkey prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 53. Turkey prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 54. Saudi Arabia prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 55. Saudi Arabia prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 56. Japan prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 57. Japan prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 58. China prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 59. China prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 60. South Korea prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 61. South Korea prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 62. India prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 63. India prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 64. Australia prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 65. Australia prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 66. Brazil prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 67. Brazil prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 68. Mexico prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 69. Mexico prevalence of MPS VI by 5-yr age cohort, females (000s)
Table 70. Argentina prevalence of MPS VI by 5-yr age cohort, males (000s)
Table 71. Argentina prevalence of MPS VI by 5-yr age cohort, females (000s)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll